Open Access<p>MicroRNA-217 acts as a tumor suppressor and correlates with the chemoresistance of cervical carcinoma to cisplatin</p>
Author(s) -
Zhaojun Yin,
Weiru Ren
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s176618
Subject(s) - cisplatin , cancer research , carcinogenesis , oncogene , flow cytometry , microrna , downregulation and upregulation , apoptosis , cervical cancer , medicine , cell growth , cancer , cell , biology , cell cycle , immunology , chemotherapy , gene , biochemistry , genetics
MicroRNA-217 (miR-217) has been demonstrated to participate in the tumorigenesis and progression of various types of cancers. Nevertheless, the role of miR-217 in cervical carcinoma still remains not fully elucidated. This current work sought to investigate the role of miR-217 in the growth, migration, and invasion of cervical carcinoma and detect the role of miR-217 in the chemosensitivity of cervical carcinoma cell to cisplatin.